{"id":"W2059075557","doi":"10.1038/nrclinonc.2014.200","title":"Current treatment landscape for relapsed and/or refractory multiple myeloma","year":2014,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Pomalidomide; Medicine; Multiple myeloma; Carfilzomib; Refractory (planetary science); Lenalidomide; Bortezomib; Oncology; Internal medicine; Regimen; Ixazomib; Disease; Thalidomide; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002836355,0.001042637,0.0112776,0.0002962011,0.0001471555,0.00002574657,0.0003270109,0.003495493,0.0001785707],"category_scores_gemma":[0.01461586,0.000523882,0.003068074,0.0003119757,0.0002464174,0.00005021519,0.0001581802,0.00311655,0.0004108569],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007192547,"about_ca_system_score_gemma":0.002097644,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000003816646,"about_ca_topic_score_gemma":0.00008288553,"domain_scores_codex":[0.991831,0.002154416,0.003282143,0.001531169,0.0003521935,0.0008490934],"domain_scores_gemma":[0.9829309,0.01290493,0.001624978,0.001207676,0.000223667,0.001107839],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001142341,0.001946139,0.0003167651,0.03000798,0.0008418986,0.0001299793,0.000006866515,2.632685e-9,4.493798e-8,0.00003056227,0.0170156,0.9485618],"study_design_scores_gemma":[0.01037007,0.01291835,0.0002068645,0.01767235,0.005076538,0.0002156211,0.000001778942,0.0000232497,8.647896e-8,0.00000999577,0.9530908,0.0004143288],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0000080402,0.9860203,0.00003038462,0.0003289691,0.001657722,0.01113121,0.0001880482,0.00007870339,0.0005565787],"genre_scores_gemma":[0.000008336415,0.98625,0.004053332,0.0003411783,0.00283261,0.003255548,0.001374163,0.0001309959,0.001753774],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9481475,"threshold_uncertainty_score":0.9997213,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2542302185574246,"score_gpt":0.5603429840524028,"score_spread":0.3061127654949782,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}